文献速递胃肠动力与功能性疾病

替那帕诺治疗便秘型肠易激综合征患者:一项2期随机安慰剂对照疗效与安全性试验

Tenapanor Treatment of Patients With Constipation-Predominant Irritable Bowel Syndrome: A Phase 2, Randomized, Placebo-Controlled Efficacy and Safety Trial.
PubMed 文献 · Am J Gastroenterol · 2017-02-28

本2期双盲试验将356例便秘型肠易激综合征(IBS-C)患者按1:1:1:1随机分配至替那帕诺5 mg、20 mg、50 mg每日两次或安慰剂每日两次治疗12周。替那帕诺50 mg每日两次组完全自发排便(CSBM)应答率显著高于安慰剂组(60.7% vs 33.7%,P<0.001),复合应答率亦显著更高(50.0% vs 23.6%,P<0.001),腹泻为最常见不良事件。

要点

  • 替那帕诺50 mg每日两次组CSBM应答率60.7%,显著高于安慰剂组33.7%(P<0.001)。
  • 替那帕诺50 mg每日两次组复合应答率50.0%,显著高于安慰剂组23.6%(P<0.001)。
  • 腹痛、腹部不适、腹胀、腹绞痛和饱胀感应答率在替那帕诺50 mg每日两次组均显著高于安慰剂组(均P<0.05)。

核心结论

  • 替那帕诺50 mg每日两次可显著增加IBS-C患者的排便频率并减轻腹部症状。
  • 作者认为值得进一步研究替那帕诺作为这些患者的潜在治疗选择。

研究设计与样本

  • 2期双盲随机安慰剂对照试验,IBS-C患者(罗马III标准)按1:1:1:1随机分配至替那帕诺5 mg、20 mg、50 mg每日两次或安慰剂每日两次,治疗12周。
  • 共随机356例患者(平均年龄45.7岁;86.8%为女性),304例完成研究。

主要发现

  • 替那帕诺50 mg每日两次组CSBM应答率60.7%,安慰剂组33.7%(P<0.001)。
  • 替那帕诺50 mg每日两次组复合应答率50.0%,安慰剂组23.6%(P<0.001)。
  • 腹痛、腹部不适、腹胀、腹绞痛和饱胀感应答率在替那帕诺50 mg每日两次组均显著高于安慰剂组(均P<0.05)。
  • 腹泻为最常见不良事件(替那帕诺每日两次:20 mg组12.4%;50 mg组11.2%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Tenapanor is a first-in-class, small-molecule inhibitor of the gastrointestinal sodium/hydrogen exchanger NHE3. This study assessed the efficacy and safety of tenapanor in patients with constipation-predominant irritable bowel syndrome (IBS-C). METHODS: In this phase 2, double-blind study, patients with IBS-C (Rome III criteria) were randomized (1:1:1:1) to receive tenapanor 5 mg, 20 mg, or 50 mg b.i.d., or placebo b.i.d. for 12 weeks. The primary end point was the complete spontaneous bowel movement (CSBM) responder rate, defined as the proportion of patients reporting an increase from baseline of ≥1 CSBM/week for ≥6/12 treatment weeks. Secondary end points included abdominal symptom responder rates (≥30% score improvement from baseline for ≥6/12 weeks) and a composite responder rate (CSBM and abdominal pain response in the same week for ≥6/12 weeks). RESULTS: Overall, 356 patients were randomized (mean age: 45.7 years; 86.8% women) and 304 completed the study. The CSBM responder rate was significantly higher in the tenapanor 50 mg b.i.d. group than in the placebo group (60.7 vs. 33.7%; P<0.001), as was the composite responder rate (50.0 vs. 23.6%; P<0.001). Responder rates for abdominal symptoms (pain, discomfort, bloating, cramping, and fullness) were significantly higher in the tenapanor 50 mg b.i.d. group than in the placebo group (all P<0.05). Diarrhea was the most frequent adverse event (tenapanor b.i.d.: 20 mg, 12.4%; 50 mg, 11.2%). CONCLUSIONS: Tenapanor 50 mg b.i.d. significantly increased stool frequency and reduced abdominal symptoms in patients with IBS-C. Further research into tenapanor as a potential treatment for these patients is justified.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Chey WD, Lembo AJ, Rosenbaum DP, et al. Tenapanor Treatment of Patients With Constipation-Predominant Irritable Bowel Syndrome: A Phase 2, Randomized, Placebo-Controlled Efficacy and Safety Trial. Am J Gastroenterol. 2017. PMID: 28244495. doi:10.1038/ajg.2017.41

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。